Literature DB >> 16160408

Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care.

Volker R Jacobs1, Jutta Thoedtmann, Uta Euler, Stefan Paepke, Thorsten Fischer, Nadia Harbeck, Marion Kiechle.   

Abstract

We report about the 2-year results of a physician-based active cost management model for oncological therapies in a German OB/GYN university clinic. Over 2 years more than 4,000 oncological cycles were prospectively and individually analyzed regarding costs and reimbursement mode. Main aim was reducing costs without lowering cycle number and standard of care. Within two years pharmaceutical costs were reduced by 83.4% or 785,976-EUR. All causes for a previous financial loss were identified and eliminated. Debts were paid back and employment of new staff and investments were possible. With this first active cost management model by and for physicians, oncological therapies can be performed cost covering even in a university clinic. Although developed for optimization of cost coverage of oncological therapies in Germany, this model is universally transferable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160408     DOI: 10.1159/000086395

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  3 in total

1.  Financial Quality Control of In-Patient Chemotherapy in Germany: Are Additional Payments Cost-Covering for Pharmaco-Oncological Expenses?

Authors:  Volker R Jacobs; Peter Mallmann
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 2.  Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic level.

Authors:  Volker R Jacobs; Gerhard Bogner; Christiane E Schausberger; Roland Reitsamer; Thorsten Fischer
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

Review 3.  A pragmatic guide on how physicians can take over financial control of their clinical practice.

Authors:  Volker R Jacobs; Thorsten Fischer
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.